Recruiting
Phase 2

Letrozole & Abemaciclib

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT06366347

Conditions

Endometrial Cancer

Recurrent Endometrial Cancer

TP53

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Abemaciclib

Letrozole

Pembrolizumab

Study Details

Brief summary:

The purpose of this research study is to see if the study drugs abemaciclib and letrozole are effective and safe for participants with estrogen-receptor positive (ER+), mismatch repair proficient, tumor protein p53 (TP53) wild-type endometrial cancer.

The names of the study drugs involved in this study are:

  • Abemaciclib (a type of cyclin-dependent kinase (CDK) inhibitor)
  • Letrozole (a type of aromatase inhibitor)

Conditions

Endometrial Cancer

Recurrent Endometrial Cancer

TP53

Study ID

NCT06366347

Start date

Sep 25, 2024

Status verified date

Aug, 2025

Completion date

Mar 1, 2029

Anticipated

Primary completion date

Sep 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants must have histologically confirmed either i) endometrioid endometrial cancer or ii) endometrial carcinosarcoma with endometrioid epithelial component.
  • Participants must have ER-positive disease, defined as ≥ 1 percent of tumor cell nuclei being immunoreactive by immunohistochemistry (IHC). If multiple analyses have been performed, judgment should be based on the most recent biopsy or pathology specimen analyzed in a CLIA (Clinical Laboratory Improvement Amendments)-certified laboratory.
  • Tumor must be TP53 wild-type as determined by immunohistochemistry (IHC) or via CLIA-certified targeted Next-Generation Sequencing (NGS); IHC assessment of p53 status is included in the NCCN guidelines of uterine neoplasms for the molecular analysis of endometrial carcinoma.
  • Participants must have mismatch repair proficient (MMRP) endometrial cancer as determined by immunohistochemistry (IHC) or polymerase chain reaction (PCR) or any CLIA-certified next generation sequencing assay.
  • No known tumor mutational burden ≥ 10 mutations/megabase (Mb).
  • No known RB1 mutations or two-copy RB1 deletion.
  • Participants must have just completed a minimum of 4 cycles and a maximum of 10 cycles of a combination of carboplatin and taxane or a combination of taxane and anti-PD-(L)1 inhibitor therapy (e.g., pembrolizumab, or dostarlimab, or durvalumab).
  • Participants must have had measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.
  • Participants are permitted to have received:

  • a. Prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy \[with or without cisplatin\])
  • b. Prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/paraaortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy. All radiation therapy must have been completed at least 4 weeks prior to registration.
  • c. Prior hormonal therapy for treatment of endometrial cancer.
  • Must be able to initiate study drug between 3 to 8 weeks (or 21 to 56 days) after completion of their final dose of chemotherapy and anti-PD-(L)1 blockade (if they were receiving anti-PD-(L)1 blockade).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix A)
  • Age ≥ 18 years
  • Participants must have normal organ and bone marrow function within 2 weeks before starting protocol therapy as defined below:

  • System Laboratory Value
  • Hematologic

  • ANC ≥1.5 × 109 /L
  • Platelets ≥100 × 109 /L
  • Hemoglobin ≥8 g/dL Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.
  • Hepatic

  • Total bilirubin ≤1.5 × ULN Patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted.
  • ALT and AST ≤3 × ULN
  • Creatinine ≤ 1.5 × institutional ULN, OR
  • Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above 1.5 x institutional ULN.
  • Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; ULN = upper limit of normal.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Ability to swallow and retain oral medication.
  • Participants must be willing to release archival tissue if available. Please see section 9.1.2 and the laboratory manual for tissue requirements.

Exclusion Criteria:

  • Participants who have received previous treatment with CDK4/6 inhibitors, including but not limited to previous abemaciclib therapy.
  • Any gastrointestinal dysfunctions that could interfere with the absorption of study drugs (e.g., bowel obstruction, inability to swallow tablets, malabsorption syndrome, unresolved nausea, vomiting, diarrhea CTCAE v 5.0 > grade 1).
  • Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to starting study treatment.
  • The patient has active systemic bacterial infection (requiring intravenous \[IV\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \[for example, hepatitis B surface antigen positive\]. Screening is not required for enrollment.
  • Major injuries or surgery within 14 days prior to start of study treatment and/or planned major surgery during the on-treatment study period. Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and starting study treatment.
  • Other malignant disease with disease-free ≤ 3 years except: curatively treated carcinoma in situ of the cervix, basal cell carcinoma of the skin, or ductal carcinoma in situ (DCIS) of the breast or any other cancer deemed by the investigator to be at low risk for recurrence of that malignancy.
  • Active brain metastases (e.g., stable for < 8 weeks, no adequate previous treatment with radiotherapy and/or surgery, symptomatic, requiring treatment with anti-convulsant therapy. Corticoid therapy is allowed if administered as stable dose for at least 1 month before starting study treatment).
  • Females who are pregnant or lactating. The effects of the study agents on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use a medically approved contraceptive method during the treatment period and for 3 months following the last dose of study agent. Contraceptive methods may include an intrauterine device (IUD) or barrier method. If condoms are used as a barrier method, a spermicidal agent should be added as a double barrier protection. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. A negative serum pregnancy test is required for study entry from women of childbearing potential.
  • The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease/pneumonitis, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance <30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  • Participants who at the time of study enrollment are known to require concomitant therapy with strong CYP3A4 inducers, or strong inhibitors of CYP3A4. Due to potential drug interactions, concomitant use of these medications is not permitted for the duration of treatment on trial. Participants are eligible for study entry if an appropriate substitution is made prior to the first dose of study medication.
  • Participants with personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
  • Individuals with a history of a different malignancy are ineligible with the following exceptions: individuals who have been treated and are disease-free for a minimum of 3 years prior to study enrollment, or individuals who are deemed by the treating investigator to be at low risk for disease recurrence.

Study Design

Enrollment

32 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Arm 1: Abemaciclib + Letrozole

Participants will be stratified by Primary Stage IVb (4b) vs. Primary Measurable Stage III (3)/IVa (4a) vs. Recurrent Endometrial Cancer and will complete study procedures as follows:

  • Baseline visit with X-ray, CT, MRI, or PET scan.
  • Cycles 1 through 3:

--Days 1 through 21 of 21 day cycle: Predetermined dose of Abemaciclib 2x per day. Predetermined dose of Letrozole 1x per day.
  • Cycle 4 and every 2 cycles thereafter:

--Days 1 through 21 of 21 day cycle: Predetermined dose of Abemaciclib 2x per day. Predetermined dose of Letrozole 1x per day.
  • X-ray, CT, MRI, or PET scan every 9 weeks for first 9 months, then every 12 months.
  • End of Treatment visit with assessments and X-ray, CT, MRI, or PET scan.
  • Follow up for up to 3 years.

Interventions

Abemaciclib

CDK inhibitor, tablet taken orally per protocol.

Letrozole

Aromatase inhibitor, tablet taken orally per protocol.

Pembrolizumab

Humanized immunoglobulin G4 monoclonal antibody, 4mL (milliliter) single-dose vial, via intravenous (into the vein) infusion per institutional standard of care.

Primary outcome measure

  • Median Progression Free Survival (PFS) [ Time Frame: Up to 2 years ]

Central Contacts and Locations

Central contacts

Panagiotis Konstantinopoulos, MD, PhD

617-632-2334Panagiotis_Konstantinopoulos@DFCI.HARVARD.EDU

Locations

Beth Israel Deaconess Medical Center

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Meghan Shea, MD

617-667-3723mshea4@bidmc.harvard.edu

Principal Investigator:

Meghan Shea, MD

Brigham and Women's Hospital

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Panagiotis Konstantinopoulos, MD, PhD

617-632-2334Panagiotis_Konstantinopoulos@dfci.harvard.edu

Principal Investigator:

Panagiotis Konstantinopoulos, MD, PhD

Dana-Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Panagiotis Konstantinopoulos, MD, PhD

617-632-2334Panagiotis_Konstantinopoulos@dfci.harvard.edu

Principal Investigator:

Panagiotis Konstantinopoulos, MD, PhD

Dana-Farber Cancer Institute at South Shore Hospital

Recruiting

Weymouth, Massachusetts, United States, 02190

Contacts

Meredith Faggen, MD

781-624-4800meredith_faggen@dfci.harvard.edu

Principal Investigator:

Meredith Faggen, MD

More Information

Sponsor

Dana-Farber Cancer Institute

Last update posted

Feb 11, 2026

Last verified

Aug, 2025

Keywords

  • TP53 wild-type endometrial cancer
  • Endometrial Cancer
  • Recurrent endometrial cancer

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2026-02-11.